Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Tel Aviv - Delayed Quote ILA

Kadimastem Ltd (KDST.TA)

2,686.00
-7.00
(-0.26%)
At close: 10:57:38 AM GMT+3
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for KDST.TA

Recent News: KDST.TA

View More
NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models

NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models
PR Newswire 19 days ago
NLS Pharmaceutics CEO Issues Letter to Shareholders

NLS Pharmaceutics CEO Issues Letter to Shareholders
PR Newswire last month
Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment
PR Newswire 2 months ago
NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies

NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies
PR Newswire 2 months ago
Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics

Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics
PR Newswire 3 months ago
NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence

NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence
PR Newswire 3 months ago
Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS

Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS
PR Newswire 3 months ago
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting at a Share Price of $3.10, Representing 48% Above the Market Share Price as of Jan 6, 2025

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting at a Share Price of $3.10, Representing 48% Above the Market Share Price as of Jan 6, 2025
PR Newswire 3 months ago
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger
PR Newswire 4 months ago
Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates

Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates
GlobeNewswire 9 months ago
IMC announces the termination of a preliminary term sheet with Kadimastem Ltd., a public company traded on the Tel Aviv Stock Exchange to fully focus on the recently legalized German market

IMC announces the termination of a preliminary term sheet with Kadimastem Ltd., a public company traded on the Tel Aviv Stock Exchange to fully focus on the recently legalized German market
CNW Group 11 months ago
View More

Related Tickers

CANF.TA Can-Fite BioPharma Ltd.
1.5000
0.00%
 
NLSP NLS Pharmaceutics AG
1.5800
+2.60%
 
CGEN.TA Compugen Ltd.
520.40
+0.21%
 
CLGN CollPlant Biotechnologies Ltd.
2.1501
-1.37%
 
TOVX Theriva Biologics, Inc.
1.3800
-1.43%
 
MDWD MediWound Ltd.
17.25
0.00%
 
NRSN NeuroSense Therapeutics Ltd.
1.0300
+0.98%
 
ALXO ALX Oncology Holdings Inc.
0.5329
+3.34%
 
WINT Windtree Therapeutics, Inc.
0.9955
-0.45%
 
AARD Aardvark Therapeutics, Inc. Common Stock
12.86
+13.50%